Unveiling the Clinical Profiles for Patients With Asthma and Chronic Obstructive Pulmonary Disease Starting Single-inhaler Triple Therapy With Fluticasone Furoate/Umeclidinium/Vilanterol (FF/ UMEC/VI)

被引：0
|
作者：
Narendra, D. [1 ]
Baptist, A. P. [2 ]
Lee, L. [3 ]
Noorduyn, S. G. [4 ]
Liu, M. [5 ]
Igboekwe, E. E. [6 ]
Veeranki, P. [5 ]
Kahle-Wrobleski, K. [7 ]
Paczkowski, R. [3 ]
机构：
[1] Baylor Coll Med, Houston, TX USA
[2] Univ Michigan, Sch Med, Ann Arbor, MI USA
[3] GSK, Value Evidence & Outcomes, Collegeville, PA USA
[4] GSK, Global Value Evidence & Outcomes, Mississauga, ON, Canada
[5] Optum, Hlth Econ & Outcomes Res, Minneapolis, MN USA
[6] GSK, US Med Affairs, Raleigh, NC USA
[7] GSK, US Med Affairs, Collegeville, PA USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2024年 / 209卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2091
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Effect of Age on Efficacy and Safety of Multiple Inhaler Triple Therapy with Umeclidinium Added to Fluticasone Furoate/Vilanterol in Chronic Obstructive Pulmonary Disease
    Soule, T.
    Caveney, S.
    Tombs, L.
    Boucot, I.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [32] The IMPACT Trial: Single Inhaler Triple Therapy fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Analysis According to Smoking Status
    Halpin, D. M. G.
    Bardsley, S.
    Criner, G.
    Dransfield, M.
    Han, M. K.
    Jones, C. E.
    Kilbride, S.
    Lomas, D. A.
    Martinez, F.
    Pascoe, S.
    Singh, D.
    Wise, R.
    Lipson, D. A.
    Lange, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [33] Fluticasone furoate, umeclidinium bromide, and vilanterol as a combination therapy for chronic obstructive pulmonary disease
    Parri, Giulia
    Nieri, Dario
    Roggi, Maria Adelaide
    Vagaggini, Barbara
    Celi, Alessandro
    Paggiaro, Pierluigi
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2018, 12 (12) : 997 - 1005
  • [34] Triple Therapy of Fluticasone Furoate, Umeclidinium, Vilanterol- A Compelling Choice in Severe Chronic Obstructive Pulmonary Disease
    Nathan, B. Jagan
    Sahay, Melina, I
    Gautham, A. K.
    Sriram, D. K.
    George, Melvin
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2021, 15 (02) : CP7 - CP7
  • [35] Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study (vol 24, 229, 2023)
    Ismaila, Afisi S.
    Rothnie, Kieran J.
    Wood, Robert P.
    Banks, Victoria L.
    Camidge, Lucinda J.
    Czira, Alexandrosz
    Compton, Chris
    Sharma, Raj
    Millard, Shannon N.
    Massey, Olivia
    Halpin, David M. G.
    RESPIRATORY RESEARCH, 2024, 25 (01)
  • [36] Budget Impact Analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma in the Dubai Academic Healthcare Corporation
    Hamouda, Mohamed
    Farghaly, Mohamed
    Al Dallal, Sara
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2023, 15 : 549 - 558
  • [37] Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis
    Afisi S. Ismaila
    Katrin Haeussler
    Alexandrosz Czira
    Ji-Hee Youn
    Mia Malmenäs
    Nancy A. Risebrough
    Jatin Agarwal
    Maria Nassim
    Raj Sharma
    Chris Compton
    Claus F. Vogelmeier
    MeiLan K. Han
    David M. G. Halpin
    Advances in Therapy, 2022, 39 : 3957 - 3978
  • [38] Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis
    Ismaila, Afisi S.
    Haeussler, Katrin
    Czira, Alexandrosz
    Youn, Ji-Hee
    Malmenas, Mia
    Risebrough, Nancy A.
    Agarwal, Jatin
    Nassim, Maria
    Sharma, Raj
    Compton, Chris
    Vogelmeier, Claus F.
    Han, MeiLan K.
    Halpin, David M. G.
    ADVANCES IN THERAPY, 2022, 39 (09) : 3957 - 3978
  • [39] InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis o the Western Europe and North America Regions
    Bourdin, Arnaud
    Criner, Gerard
    Devouassoux, Gilles
    Dransfield, Mark
    Halpin, David M. G.
    Han, MeiLan K.
    Jones, C. Elaine
    Kalhan, Ravi
    Lange, Peter
    Lettis, Sally
    Lipson, David A.
    Lomas, David A.
    Maria-Tome, Jose M. Echave-Sustaeta
    Martin, Neil
    Martinez, Fernando J.
    Quasny, Holly
    Sail, Lynda
    Siler, Thomas M.
    Singh, Dave
    Thomashow, Byron
    Watz, Henrik
    Wise, Robert
    Hanania, Nicola A.
    CHRONIC OBSTRUCTIVE PULMONARY DISEASES-JOURNAL OF THE COPD FOUNDATION, 2021, 8 (01): : 76 - 90
  • [40] THE IMPACT TRIAL: COST-EFFECTIVENESS ANALYSIS OF SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS DUAL BRONCHODILATOR THERAPY (UMEC/VI) IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN SPAIN
    Vallejo-Aparicio, L. A.
    Paly, V. F.
    Schroeder, M.
    Martin, A.
    Risebrough, N.
    Abreu, C.
    Biswas, C.
    Izquierdo Alonso, J. L.
    Riesco Miranda, J. A.
    Soler Cataluna, J. J.
    Ismaila, A. S.
    VALUE IN HEALTH, 2019, 22 : S878 - S878
12345